FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

708 letters match. Newest first.

  1. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  2. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  3. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  4. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  5. BioMylz Pvt. Ltd.

    FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.

    High risk
  6. Mineral BioSciences, LLC

    Mineral BioSciences’ Totala and Ionicell supplements were flagged as unapproved new drugs and misbranded, with manufacturing violations.

    High risk
  7. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  8. Allandale Dairy

    Allandale Dairy sold a cow for slaughter whose liver held sulfadimethoxine above the allowed level, and misused drugs.

    High risk
  9. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk
  10. Genzyme Ireland Limited

    Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.

    High risk
  11. Golden Dakota Farms LLC

    South Dakota dairy sold cows for slaughter with ampicillin residues above the legal limit and gave one cow an unapproved overdose.

    High risk
  12. Sante Manufacturing Inc.

    Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.

    High risk
  13. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  14. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  15. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  16. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  17. Erkul Kozmetik Sanayi ve Ticaret A.S.

    Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.

    High risk
  18. PLZ Corp

    FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.

    High risk
  19. Asanuma Corporation - Sagamihara Factory

    FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.

    High risk
  20. Shantou Qiwei Industry Co., LTD

    FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

    High risk
  21. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk
  22. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  23. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  24. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  25. Alchymars ICM SM Private Limited

    FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.

    High risk
  26. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk
  27. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  28. Best Buy Bones, Inc.

    Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.

    High risk
  29. Shineluck Foods, Inc.

    FDA warns Shineluck Foods that its mung bean sprouts were held under insanitary conditions with pathogen testing and monitoring failures.

    High risk
  30. La Crema De Rebeca

    La Crema De Rebeca's skin-lightening cream is an unapproved, misbranded drug containing high mercury, FDA warns.

    High risk
  31. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  32. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  33. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  34. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  35. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  36. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  37. DO&CO Aktiengesellschaft/DO&CO, Inc.

    DO&CO airline catering facilities in New York and Michigan had repeated Listeria monocytogenes contamination and sanitation failures.

    High risk
  38. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  39. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  40. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  41. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  42. Pro Numb Tattoo Numbing Spray, LLC

    FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.

    High risk
  43. UCSF Radiopharmaceutical Facility

    FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.

    High risk
  44. Xiamen Kang Zhongyuan Biotechnology Co., Ltd.

    FDA found filthy conditions and falsified records at Chinese drug maker Xiamen Kang Zhongyuan; cough drops recalled, imports blocked.

    High risk
  45. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  46. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  47. Chemco Corporation

    FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.

    High risk
  48. Purolea Cosmetics Lab

    Purolea Cosmetics Lab drug products were adulterated by insanitary conditions and manufacturing failures, and two Dermveda products are unapproved new drugs.

    High risk
  49. Microbiological Testing & Consulting, LLC

    FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.

    High risk
  50. Physitemp Instruments, LLC

    FDA says Physitemp sold clinical thermometers and temperature probes without FDA clearance and with unvalidated sterilization and welding.

    High risk